Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
US Department of Justice
Fish and Richardson
Merck
Johnson and Johnson
Express Scripts
Colorcon
Chubb
Citi
Federal Trade Commission

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,592,339

« Back to Dashboard

Summary for Patent: 7,592,339
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/460,529
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,592,339

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETON OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Sign Up ➤ Sign Up PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Sign Up ➤ Sign Up REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,592,339

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,157,456 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,129,378 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,530,505 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,822,458 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
7,576,111 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
7,585,860 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,592,339

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200422299 ➤ Sign Up
Taiwan I226330 ➤ Sign Up
Turkey 200401314 ➤ Sign Up
Turkey 200201636 ➤ Sign Up
El Salvador 2002000245 ➤ Sign Up
Slovakia 287272 ➤ Sign Up
Slovakia 9082002 ➤ Sign Up
Slovenia 1526132 ➤ Sign Up
Slovenia 1261606 ➤ Sign Up
Singapore 130939 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Fish and Richardson
QuintilesIMS
McKesson
Merck
Covington
Dow
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot